2016
RARE-39. INTRAVASCULAR LYMPHOMA AFFECTING THE CENTRAL NERVOUS SYSTEM: FEATURES AND OUTCOMES IN A CASE SERIES OF THE PRIMARY CNS LYMPHOMA COLLABORATIVE GROUP (IPCG)
Zukas A, Bennani N, Chou C, Johnston P, O’Neill B, Nijland M, Batchelor T, Nayak L, Mrugala M, Low J, Omuro A, Ferreri A, Nishikawa R, Mishima K, Fox C, Wilson W, Houillier C, Chamberlain M, Schiff D. RARE-39. INTRAVASCULAR LYMPHOMA AFFECTING THE CENTRAL NERVOUS SYSTEM: FEATURES AND OUTCOMES IN A CASE SERIES OF THE PRIMARY CNS LYMPHOMA COLLABORATIVE GROUP (IPCG). Neuro-Oncology 2016, 18: vi168-vi168. DOI: 10.1093/neuonc/now212.702.Peer-Reviewed Original ResearchCentral nervous systemIntravascular lymphomaOne-year survivalCase seriesCombination therapyTreatment outcomesEastern Cooperative Oncology Group performance statusNervous systemCommon first-line treatmentMedian progression-free survivalHigh-dose methotrexate therapyLarge B-cell typePrimary central nervous systemLarge B-cell lymphomaHigh-dose methotrexatePercent of patientsPoor functional statusFirst-line treatmentPrimary CNS lymphomaProgression-free survivalStroke-like symptomsMean diagnostic delayRetrospective case seriesTime of diagnosisTime of presentation
2014
Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients
Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, Colman H, Dhall G, Lieberman FS, Metellus P, Mikkelsen T, Omuro A, Partap S, Prados M, Robins HI, Soffietti R, Wu J, Gilbert MR, Armstrong TS. Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro-Oncology 2014, 17: 440-447. PMID: 25121770, PMCID: PMC4483095, DOI: 10.1093/neuonc/nou162.Peer-Reviewed Original ResearchConceptsProgression-free survivalClinical courseEpendymoma patientsMultivariate Cox proportional hazards modelMultivariate Cox proportional hazardsCox proportional hazards modelRare CNS tumorsTime of diagnosisPrognostic clinical factorsCox proportional hazardsProportional hazards modelSubtotal resectionClinical factorsMedian timeCNS tumorsCentral reviewGrade IIIMean ageTumor recurrenceEarly progressionTumor locationGrade IITumor gradeUnivariate analysisSupratentorial location
2005
Salvage temozolomide for prior temozolomide responders
Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE. Salvage temozolomide for prior temozolomide responders. Cancer 2005, 104: 2473-2476. PMID: 16270316, DOI: 10.1002/cncr.21564.Peer-Reviewed Original ResearchConceptsDisease recurrenceRecurrent/progressive gliomaInitial disease recurrencePotential hematologic complicationsSubsequent salvage therapyFirst-line therapyProgression-free survivalTime of diagnosisLow-grade oligodendrogliomasWarrants further investigationSalvage therapyStable diseaseHematologic complicationsObjective responseRadiographic responseMedian ageRetrospective reviewDisease progressionTMZ treatmentAnaplastic astrocytomaPatientsProgressive gliomasRecurrenceTemozolomideSame agents